BIO BIO-RAD LABORATORIES, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 12208 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY251.3%
TTM EPS YoY254.8%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—
Margins
Gross margin51.3%
Operating margin-2.4%
Net margin39.5%
FCF margin12.7%
EBITDA margin—
Returns
ROE14.3%
ROA10.0%
ROIC (approx.)-0.6%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets29.5%
Debt / equity0.11x
Current ratio3.18x
Interest coverage-1.27x
Cash quality & payout
Operating cash flow / net income0.46x
Accruals ratio5.4%
Payout ratio—
Capex / revenue5.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B |
| R&D expense | $275.60M | $295.90M | $247.40M | $256.90M | $260.64M |
| SG&A expense | $844.30M | $814.00M | $841.70M | $827.80M | $877.12M |
| Operating income | $47.20M | $269.00M | $337.80M | $482.60M | $500.34M |
| Interest expense | $49.00M | $48.90M | $49.40M | $38.10M | $1.55M |
| Pretax income | $995.50M | -$2.34B | -$850.10M | -$4.70B | $5.45B |
| Income tax | $235.60M | -$498.30M | -$212.80M | -$1.08B | $1.19B |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | $4.25B |
| EBITDA | $212.60M | $420.60M | $483.70M | $619.90M | $637.94M |
| EPS (basic) | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 |
| EPS (diluted) | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
| Weighted avg. shares (diluted) | 27.28M | 28.21M | 29.21M | 29.79M | 30.21M |
| Banking | |||||
| Provision for credit losses | $1.40M | $0 | $0 | $7.50M | $0 |
| Balance sheet | |||||
| Cash & equivalents | $529.80M | $489.80M | $403.80M | $434.50M | $471.10M |
| Short-term investments | $1.01B | $1.18B | $1.20B | $1.36B | $399.13M |
| Receivables | $460.60M | $452.50M | $489.00M | $494.64M | $423.54M |
| Inventory | $740.70M | $760.00M | $780.50M | $719.32M | $572.24M |
| Current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B |
| PP&E, net | $539.90M | $528.10M | $529.00M | $498.61M | $511.64M |
| Goodwill | $579.80M | $410.50M | $413.60M | $406.50M | $347.30M |
| Intangibles | $174.30M | $293.60M | $320.50M | $332.15M | $253.94M |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B |
| Current liabilities | $517.00M | $467.80M | $522.80M | $568.71M | $680.94M |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | $10.51M |
| Total debt | $1.20B | $1.20B | $1.20B | $1.20B | $10.51M |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B |
| Shareholders' equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B |
| Net debt | $671.90M | $710.60M | $795.30M | $763.20M | -$460.59M |
| Cash flow statement | |||||
| Operating cash flow | $532.20M | $455.20M | $374.90M | $194.40M | $669.46M |
| Capital expenditure | $157.60M | $165.60M | $156.70M | $112.80M | $133.75M |
| Free cash flow | $374.60M | $289.60M | $218.20M | $81.60M | $535.72M |
| Investing cash flow | -$189.70M | -$160.20M | $20.20M | -$1.21B | -$797.38M |
| Financing cash flow | -$283.20M | -$218.80M | -$425.60M | $973.60M | -$55.43M |
| Depreciation & amortization | $165.40M | $151.60M | $145.90M | $137.30M | $137.60M |
| Stock-based compensation | $58.00M | $62.30M | $61.30M | $60.90M | $51.20M |
| Share buybacks | $295.50M | $203.60M | $428.70M | $215.70M | $50.00M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.